Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- QDEL -39.3%, UPST -13.9%, BL -11.7%, GNRC -7.6%, CART -5.7% (also COO to step down; announces restructuring plan, includes 7% workforce reduction; also authorizes additional $500 mln for share repurchases), AKAM -5.4%, ABNB -4.7% (also authorizes a new repurchase program of up to $6.0 bln), MGM -3.5%, CRK -3.5%, CRSR -3%, GPN -2.6%, SAH -2.5%, MODG -2.4%, GDDY -2.4%, EQT -1.9%, AVTR -1.5%, SITM -1.3%, KHC -1.1%, LAD -1%, CNHI -0.8%
Other news:
- IMNM -8.8% (prices offering of 10 mln shares of common stock at $20.00 per share)
- CC -8.2% (reschedules earnings release)
- NAMS -5% (prices $175.3 mln offering of ordinary shares and pre-funded warrants)
- MACK -1.7% (FDA approves Ipsen's Onivyde regimen which triggers milestone payment to MACK)
- GRFS -1.5% ( announces topline phase 3 fibrinogen clinical trial results)
- SCVL -1.3% (acquires Rogan Shoes guides FY24 in-line)
Analyst comments:
- MGNX -3.3% (downgraded to Neutral from Buy at H.C. Wainwright)
- GDDY -2.4% (downgraded to In-line from Outperform at Evercore ISI)
- INCY -2.1% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities)
- ECL -1.6% (downgraded to Neutral from Overweight at JP Morgan)
- TGLS -1.5% (downgraded to Hold from Buy at Stifel)
- GFS -0.8% (downgraded to Neutral from Buy at Citigroup)